The collaboration pools the resources of UNC's schools of Medicine and Public Health, Duke University Medical Center and Duke's Terry Sanford Institute of Public Policy to design and implement educational and research initiatives that promise long-term public health improvements in each of the four areas. It is under the direction of principal investigators Dr. Victor J. Dzau, Duke's chancellor for health affairs and president and chief executive officer of the Duke University Health System; and Dr. William L. Roper, UNC's vice chancellor for medical affairs, UNC Health Care's chief executive officer, and dean of the UNC School of Medicine.
"By funding this powerful collaboration, GlaxoSmithKline enables Duke and UNC to pool our extensive strengths in research design, evidence-based medicine, public health and public policy, and community-based initiatives to design models that can be disseminated locally and globally," Dzau said. "We are very grateful for GlaxoSmithKline's partnership and we look forward to the far-reaching and sustainable impact of this and future collaborations between our two institutions."
Said Roper, "This is yet another example of the enormous potential that can be realized by UNC working in concert with our colleagues in Durham. GlaxoSmithKline recognizes that the outcome of this partnership will be better health care for all. I want to express my appreciation to the North Carolina GlaxoSmithKline Foundation for making it a reality, and I look forward to the good work ahead of us."
The three-year grant period began Jan. 6 and includes a six-month plannin
'"/>
Contact: Karen McCall
kmccall@unch.unc.edu
919-966-4752
University of North Carolina at Chapel Hill
7-Feb-2006